Ananda Pharma (STU:1FX) OCF Yield %: -34.50 (As of Jul. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Ananda Pharma OCF Yield %?

Ananda Pharma STU:1FX OCF Yield % is -34.50 as of Jul. 22, 2026. The stock has 5 warning signs investors should review. Among 1,005 Drug Manufacturers companies, Ananda Pharma ranks worse than 94.43% on this metric.

OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

As of today, Ananda Pharma's Trailing 12-Month Cash Flow from Operations is €0.00 Mil, and Market Cap is €2.15 Mil. Therefore, Ananda Pharma's OCF Yield % for today is -34.50%.

The historical rank and industry rank for Ananda Pharma's OCF Yield % or its related term are showing as below:

STU:1FX' s OCF Yield % Range Over the Past 10 Years
Min: -34.5   Med: 0   Max: -34.5
Current: -34.5


During the past 7 years, the highest OCF Yield % of Ananda Pharma was -34.50%. The lowest was -34.50%. And the median was %.

STU:1FX's OCF Yield % is ranked worse than
94.43% of 1005 companies
in the Drug Manufacturers industry
Industry Median: 3.65 vs STU:1FX: -34.50

Ananda Pharma's OCF Margin % for the quarter that ended in Jul. 2025 was %.


Ananda Pharma OCF Yield % Explanation

Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Ananda Pharma OCF Yield % Related Terms


Ananda Pharma OCF Yield % Historical Data

* Premium members only.

The historical data trend for Ananda Pharma's OCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ananda Pharma OCF Yield % Chart

Ananda Pharma Annual Data
Trend Jan19 Jan20 Jan21 Jan22 Jan23 Jan24 Jan25
OCF Yield %
Get a 7-Day Free Trial 0.00 0.00 -13.04 -14.63 -6.47

Ananda Pharma Semi-Annual Data
Jul18 Jan19 Jul19 Jan20 Jul20 Jan21 Jul21 Jan22 Jul22 Jan23 Jul23 Jan24 Jul24 Jan25 Jul25
OCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

STU:1FX vs ZTS, UTHR, VTRS: OCF Yield % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Ananda Pharma's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ananda Pharma OCF Yield % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ananda Pharma's OCF Yield % distribution charts can be found below:

* The bar in red indicates where Ananda Pharma's OCF Yield % falls into.



Ananda Pharma OCF Yield % Calculation

OCF Yield % is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

Ananda Pharma's OCF Yield % for the fiscal year that ended in Jan. 2025 is calculated as

OCF Yield %=Cash Flow from Operations / Market Cap
=-0.974 / 15.0470145
=-6.47%

Ananda Pharma's annualized OCF Yield % for the quarter that ended in Jul. 2025 is calculated as

OCF Yield %=Cash Flow from Operations * Annualized Factor / Market Cap
=0 * 2 / 8.598294
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Yield % →
What does a OCF Yield % of -34.50 mean?
Ananda Pharma (STU:1FX) has a OCF Yield % of -34.50 as of Jul. 22, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Ananda Pharma and its competitors. According to the industry distribution chart, Ananda Pharma ranks #949 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 94.4%.
Is Ananda Pharma's OCF Yield % too high?
Ananda Pharma's current OCF Yield % is -34.50. Based on the distribution chart, Ananda Pharma ranks #949 out of 1005 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Ananda Pharma's OCF Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Ananda Pharma ranks #949 out of 1005 companies for OCF Yield %. This places Ananda Pharma in the lower half of its industry. The industry median OCF Yield % is 3.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Drug Manufacturers company?
The median OCF Yield % among Drug Manufacturers companies is 3.65, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Ananda Pharma and its competitors. For the Drug Manufacturers industry, the median OCF Yield % is 3.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ananda Pharma's current OCF Yield % is -34.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ananda Pharma stock overvalued right now?
Ananda Pharma (STU:1FX) has a current OCF Yield % of -34.50. The current OCF Yield % is -34.50. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Ananda Pharma (STU:1FX), the current OCF Yield % is -34.50 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ananda Pharma Business Description

Address 60 Gracechurch Street, 6th Floor, London, GBR, EC3V 0HR
Ananda Pharma PLC is a UK-based biopharmaceutical company developing regulatory-approved, cannabidiol medicines to treat complex, chronic conditions, including endometriosis (funded by NHS Scotland) and chemotherapy-induced peripheral neuropathy (funded by NIHR).